; (vii) agrees that, pursuant to subsection (g), laboratories approved by the Secretary may be authorized to conduct insulin testing to determine the chemical authenticity of sample insulin products; (viii) agrees to notify the Secretary, importers, and individuals of insulin recalls in Canada, or pursuant to subsection (e), the permitted country in which the seller is located, and agrees to cease, or refrain from, exporting such insulin; (ix) has established, or will establish or participate in, a process for resolving grievances, as defined by the Secretary, and will be held accountable for violations of established guidelines and rules; (x) except as otherwise permitted under this section, does not sell products that the seller could not otherwise legally sell in Canada, or, subject to subsection (e), the permitted country in which such seller is located to customers in the United States